Complete and durable clinical response of malignant pyoderma to tacrolimus in combination with dapsone and prednisone.
Ciurea
Ana M
AM
Guitart
Joan
J
Brieva
Joaquin
J
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D017511:Pyoderma Gangrenosum / Q000175:diagnosis / Q000188:drug therapy*; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003622:Dapsone; D011241:Prednisone; D016559:Tacrolimus